UA96045C2 - Амидное производное для ингибирования роста раковых клеток - Google Patents

Амидное производное для ингибирования роста раковых клеток

Info

Publication number
UA96045C2
UA96045C2 UAA200913594A UAA200913594A UA96045C2 UA 96045 C2 UA96045 C2 UA 96045C2 UA A200913594 A UAA200913594 A UA A200913594A UA A200913594 A UAA200913594 A UA A200913594A UA 96045 C2 UA96045 C2 UA 96045C2
Authority
UA
Ukraine
Prior art keywords
cancer cells
growth
amide derivative
inhibiting
overexpression
Prior art date
Application number
UAA200913594A
Other languages
English (en)
Ukrainian (uk)
Inventor
Кванг-Ок Ли
Ми Йоунг Ча
Ми Ра Ким
Йоунг Хее ДЗУНГ
Чанг Гон Ли
Се Йоунг Ким
Кеукчан Банг
Бум Воо ПАРК
Бо Им Чои
Юн Дзунг Чаэ
Ми Йоунг Ко
Хан Кионг КИМ
Йоунг-Гил Ахн
Маенг Суп КИМ
Гван Сун ЛИ
Original Assignee
Ханми Фарм. Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханми Фарм. Ко., Лтд. filed Critical Ханми Фарм. Ко., Лтд.
Publication of UA96045C2 publication Critical patent/UA96045C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение касается нового амидного производного и его фармацевтически приемлемой соли, которое селективно и эффективно ингибирует рост раковых клеток, вызванный сверхэкспрессией рецептора эпидермального фактора роста (EGFR), и также предотвращает развитие лекарственной устойчивости, вызванной мутацией EGFR тирозинкиназы, и фармацевтической композиции, которая содержит его как активный ингредиент.
UAA200913594A 2007-06-05 2008-06-05 Амидное производное для ингибирования роста раковых клеток UA96045C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20070054997 2007-06-05

Publications (1)

Publication Number Publication Date
UA96045C2 true UA96045C2 (ru) 2011-09-26

Family

ID=40094307

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200913594A UA96045C2 (ru) 2007-06-05 2008-06-05 Амидное производное для ингибирования роста раковых клеток

Country Status (25)

Country Link
US (1) US8188102B2 (ru)
EP (1) EP2167492B1 (ru)
JP (1) JP5155391B2 (ru)
KR (1) KR101013319B1 (ru)
CN (1) CN101679384B (ru)
AR (2) AR066876A1 (ru)
AU (1) AU2008260772B2 (ru)
BR (1) BRPI0811069B1 (ru)
CA (1) CA2687180C (ru)
DK (1) DK2167492T3 (ru)
ES (1) ES2558623T3 (ru)
HK (1) HK1142591A1 (ru)
HR (1) HRP20160007T1 (ru)
HU (1) HUE028243T2 (ru)
IL (1) IL202154A (ru)
MX (1) MX2009012772A (ru)
MY (1) MY144972A (ru)
NZ (1) NZ582412A (ru)
PL (1) PL2167492T3 (ru)
PT (1) PT2167492E (ru)
RU (1) RU2434010C2 (ru)
TW (1) TWI377944B (ru)
UA (1) UA96045C2 (ru)
WO (1) WO2008150118A2 (ru)
ZA (1) ZA201000022B (ru)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002585A (es) 2006-09-11 2009-08-24 Curis Inc Inhibidores e egfr a base de quinolina que contienen porcion de enlace de zinc.
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
JP5918693B2 (ja) 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｅｇｆｒ阻害剤及び疾患の治療方法
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
KR101272613B1 (ko) * 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
CN110194748A (zh) 2012-01-13 2019-09-03 艾森生物科学公司 杂环化合物及其作为抗癌药的用途
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
CA2860765C (en) 2012-01-17 2018-06-26 Astellas Pharma Inc. Pyrazinecarboxamide compound
CN102659764A (zh) * 2012-04-16 2012-09-12 中国科学院广州生物医药与健康研究院 酪氨酸激酶不可逆抑制剂及其制备方法和用途
KR20140096571A (ko) * 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
BR112016000195A8 (pt) 2013-07-11 2019-12-31 Acea Biosciences Inc compostos heterocíclicos, composição farmacêutica, combinação, seu uso, e método para inibir uma atividade da tirosina quinase btk ou jak, egfr, alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, e suas respectivas vias
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
WO2015154725A1 (zh) * 2014-04-11 2015-10-15 四川海思科制药有限公司 喹唑啉衍生物及其制备方法和在医药上的应用
EP3226869A4 (en) * 2014-12-03 2018-07-18 Auckland UniServices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
CN107406430B (zh) * 2015-03-20 2019-04-26 正大天晴药业集团股份有限公司 喹唑啉衍生物的盐及其制备方法
JP6889494B2 (ja) 2015-10-09 2021-06-18 エイシア セラピューティクス， インコーポレイテッド ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法
US10858340B2 (en) * 2016-08-25 2020-12-08 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Crystal of salt of quinazoline derivative
CN108069946B (zh) * 2016-11-08 2020-06-05 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的取代的喹唑啉化合物
CN110167928A (zh) * 2016-12-22 2019-08-23 勃林格殷格翰国际有限公司 作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018157813A1 (zh) 2017-02-28 2018-09-07 南京明德新药研发股份有限公司 螺环类化合物及其应用
BR112019020840A2 (pt) 2017-04-07 2020-04-28 Acea Therapeutics Inc sais farmacêuticos, formas físicas e composições de inibidores da pirrolopirimidina quinase e métodos de produção dos mesmos
ES2888298T3 (es) * 2017-04-27 2022-01-03 Astrazeneca Ab Compuestos de C5-anilinoquinazolina y su uso en el tratamiento de cáncer
AR113451A1 (es) * 2017-10-18 2020-05-06 Spectrum Pharmaceuticals Inc Inhibidores de tirosina quinasas de la familia de los egfr mutantes
EP3733663B1 (en) * 2017-12-19 2023-05-17 Chengdu Jinrui Foundation Biotech Co., Ltd. 1-[6-[[4-(phenylamino)-6-quinazolinyl]oxy]-3-azabicyclo[3.1.1]hept-3-yl]-2-propen-1-one derivatives and related compounds as irreversible inhibitors of pan-her tyrosine kinase for the treatment of cancer
CN111372932B (zh) 2017-12-21 2023-11-21 勃林格殷格翰国际有限公司 作为sos1抑制剂的新颖苄氨基取代吡啶并嘧啶酮及衍生物
BR112020019251A2 (pt) 2018-03-27 2021-01-12 Board Of Regents, The University Of Texas System Compostos com atividade anti-tumor contra células de câncer com mutações de her2 exon 19
CN110054613B (zh) * 2018-05-24 2020-11-27 深圳市塔吉瑞生物医药有限公司 取代的氨基喹唑啉类化合物及其药物组合物及其用途
CN110577514B (zh) * 2018-06-08 2022-07-05 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
WO2019233459A1 (zh) * 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 人表皮生长因子受体抑制剂及其制备方法和应用
CN108623490A (zh) * 2018-06-22 2018-10-09 苏州市贝克生物科技有限公司 (2z)-4-(二甲基氨基)-2-丁烯酸盐酸盐的合成方法
US20210145834A1 (en) 2018-06-25 2021-05-20 Spectrum Pharmaceuticals, Inc. Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
TW202012391A (zh) * 2018-07-04 2020-04-01 日商第一三共股份有限公司 二芳基醚型喹唑啉衍生物
KR20210061371A (ko) * 2018-09-14 2021-05-27 스펙트럼 파마슈티컬즈 인크 암 치료용 키트 및 방법
CN113056272A (zh) * 2018-09-21 2021-06-29 光谱医药公司 新的喹唑啉egfr抑制剂
CN113382986A (zh) 2018-09-25 2021-09-10 黑钻治疗公司 酪氨酸激酶抑制剂组合物、其制备方法和使用方法
KR101950942B1 (ko) 2019-01-28 2019-02-22 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
MA55380A (fr) 2019-03-19 2022-01-26 B2Sbio Inc Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace
JP2022529518A (ja) * 2019-04-25 2022-06-22 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム チロシンキナーゼの複素環式阻害剤
JP2022534555A (ja) 2019-05-09 2022-08-02 フジフィルム セルラー ダイナミクス，インコーポレイテッド ヘパトサイトの作製方法
US20220242851A1 (en) * 2019-06-19 2022-08-04 Shenzhen Jinrui Foundation Biotech Co., Ltd Crystal form and salt of quinazoline compound and preparation method thereof
WO2020262998A1 (ko) * 2019-06-26 2020-12-30 한미약품 주식회사 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물
KR20210049004A (ko) 2019-10-24 2021-05-04 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체를 포함하는 약제학적 제제 및 이를 포함하는 약제학적 제품
WO2021127397A1 (en) * 2019-12-19 2021-06-24 Black Diamond Therapeutics, Inc. Nitrogen heterocyclic compounds and methods of use
US20230121116A1 (en) * 2020-01-29 2023-04-20 Board Of Regents, The University Of Texas System Use of quinazoline-based tyrosine kinase inhibitors for the treatment of cancers with nrg1 fusions
WO2021231400A1 (en) * 2020-05-12 2021-11-18 Accutar Biotechnology, Inc. Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors
CN111763215B (zh) * 2020-07-21 2021-05-18 成都海博为药业有限公司 一种具有含氮杂环结构的化合物及其制备方法和用途
WO2022105908A1 (zh) * 2020-11-23 2022-05-27 上海和誉生物医药科技有限公司 Egfr抑制剂及其制备方法与在药学上的应用
WO2022170043A1 (en) * 2021-02-05 2022-08-11 Accutar Biotechnology, Inc. Quinazoline derived compounds as egfr inhibitors and their uses thereof
WO2022265950A1 (en) 2021-06-15 2022-12-22 Genentech, Inc. Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
WO2022266427A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 4-(aryl-methyl-amino)-quinazoline derivatives and uses thereof
WO2022266426A1 (en) * 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof
CA3229692A1 (en) * 2021-08-24 2023-03-02 Shunqi Yan Quinazoline compounds for treatment of disease
CN115894486B (zh) * 2021-09-30 2024-02-09 北京赛特明强医药科技有限公司 一种氢化吡啶并喹唑啉类化合物、组合物及其应用
WO2023128350A1 (ko) * 2021-12-30 2023-07-06 주식회사 비투에스바이오 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2024083120A1 (zh) * 2022-10-18 2024-04-25 南京明德新药研发有限公司 苄氨基喹啉类化合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
AU2003226705B2 (en) 2002-03-30 2008-11-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
MXPA06001079A (es) * 2003-07-29 2006-04-11 Astrazeneca Ab Derivados de piperidil quinazolina como inhibidores de cinasa de tirosina.
EP1664028A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
BRPI0414735A (pt) * 2003-09-25 2006-11-21 Astrazeneca Ab derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina
EP1734040A4 (en) 2004-03-23 2007-11-28 Banyu Pharma Co Ltd SUBSTITUTED CHINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE
WO2007023073A2 (de) * 2005-08-22 2007-03-01 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2007055513A1 (en) * 2005-11-08 2007-05-18 Hanmi Pharm. Co., Ltd. Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof

Also Published As

Publication number Publication date
AU2008260772B2 (en) 2011-06-02
AR066876A1 (es) 2009-09-16
BRPI0811069B1 (pt) 2022-08-30
EP2167492B1 (en) 2015-10-14
NZ582412A (en) 2011-12-22
HUE028243T2 (en) 2016-12-28
KR101013319B1 (ko) 2011-02-09
AU2008260772A1 (en) 2008-12-11
WO2008150118A2 (en) 2008-12-11
HRP20160007T1 (hr) 2016-02-12
CA2687180C (en) 2012-07-24
ZA201000022B (en) 2011-04-28
MX2009012772A (es) 2009-12-15
EP2167492A2 (en) 2010-03-31
EP2167492A4 (en) 2010-12-15
PT2167492E (pt) 2016-02-04
CN101679384B (zh) 2013-10-16
MY144972A (en) 2011-11-30
US20100179120A1 (en) 2010-07-15
CN101679384A (zh) 2010-03-24
TWI377944B (en) 2012-12-01
JP5155391B2 (ja) 2013-03-06
HK1142591A1 (en) 2010-12-10
KR20080107294A (ko) 2008-12-10
RU2009149307A (ru) 2011-07-20
US8188102B2 (en) 2012-05-29
IL202154A0 (en) 2010-06-16
TW200906414A (en) 2009-02-16
RU2434010C2 (ru) 2011-11-20
BRPI0811069A2 (pt) 2014-12-09
WO2008150118A3 (en) 2009-01-29
CA2687180A1 (en) 2008-12-11
IL202154A (en) 2014-05-28
JP2010529115A (ja) 2010-08-26
PL2167492T3 (pl) 2016-03-31
AR110003A2 (es) 2019-02-13
ES2558623T3 (es) 2016-02-05
DK2167492T3 (en) 2016-01-11

Similar Documents

Publication Publication Date Title
MY144972A (en) Novel amide derivative for inhibiting the growth of cancer cells
WO2008060907A3 (en) Pyrrolo-pyridine kinase inhibitors
WO2011099764A3 (en) Novel pyrimidine derivative for inhibiting the growth of cancer cells
UA99141C2 (ru) Замещенные производные индазола, активные в качестве ингибиторов киназы
MX2007007458A (es) Derivados de quinazolina para inhibir crecimiento de celulas cancerigenas y metodo para la preparacion de los mismos.
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2007044796A3 (en) Pyridazinone compounds as calcilytics
PH12015501483A1 (en) Heterocyclic compounds and uses thereof
UA99284C2 (ru) ИНГИБИТОРЫ р70 S6-КИНАЗЫ
WO2009007390A3 (en) 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors
PL2324008T3 (pl) 3,4-diarylopirazole jako inhibitory kinazy białkowej
WO2011093672A3 (en) Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase
MX2009002010A (es) Derivados de heteroarilo como inhibidores de la proteina cinasa.
CY1113642T1 (el) Γεφυρωμενες δικυκλικες ετεροαρυλ υποκατεστημενες τριαζολες, χρησιμες ως αναστολεις της axl
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2008080134A3 (en) 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
EP2476679A3 (en) Substituted triazoles useful as AXL inhibitors
AU2011297889A8 (en) Pharmaceutically active compounds as Axl inhibitors
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
BRPI0713555A2 (pt) ciclopenta [d] pirimidinas como inibidores de akt protéina cinase
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
SI2054418T1 (sl) Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
TNSN08191A1 (en) Kinase inhibitors